RG
CLVS

Redmile Group’s Clovis Oncology, Inc. CLVS Stock Holding History

Redmile Group’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-99,485
Closed -$633K – 89
2020
Q1 		$633K Buy
+99,485
New +$798K 0.02% 64
2019
Q4 		– Sell
-3,607,800
Closed -$14.2M – 80
2019
Q3 		$14.2M Buy
3,607,800
+145,500
+4% +$1.18M 0.47% 48
2019
Q2 		$51.5M Sell
3,462,300
-1,101,629
-24% -$19.9M 1.46% 22
2019
Q1 		$113M Buy
4,563,929
+503,400
+12% +$12.6M 3.31% 6
2018
Q4 		$72.9M Buy
4,060,529
+2,282,229
+128% +$46.6M 2.93% 10
2018
Q3 		$52.2M Buy
1,778,300
+19,700
+1% +$763K 1.61% 21
2018
Q2 		$80M Buy
+1,758,600
New +$85.5M 2.72% 11
2018
Q1 		– Sell
-1,320,027
Closed -$89.8M – 76
2017
Q4 		$89.8M Buy
1,320,027
+323,417
+32% +$22.6M 3.9% 4
2017
Q3 		$82.1M Buy
996,610
+232,221
+30% +$18.4M 4.05% 5
2017
Q2 		$71.6M Sell
764,389
-208,307
-21% -$12.7M 4.36% 5
2017
Q1 		$61.9M Sell
972,696
-647,659
-40% -$39.4M 4.02% 5
2016
Q4 		$72M Sell
1,620,355
-429,630
-21% -$15.1M 6.2% 3
2016
Q3 		$73.9M Sell
2,049,985
-1,047,865
-34% -$22.5M 5.88% 4
2016
Q2 		$42.5M Sell
3,097,850
-1,486
-0% -$21.7K 4.06% 8
2016
Q1 		$59.5M Buy
3,099,336
+1,303,400
+73% +$27.6M 6.09% 3
2015
Q4 		$62.9M Buy
1,795,936
+838,302
+88% +$54.1M 4.7% 6
2015
Q3 		$88.1M Buy
957,634
+198,155
+26% +$17.1M 6.67% 2
2015
Q2 		$66.7M Sell
759,479
-141,400
-16% -$12.1M 5.47% 4
2015
Q1 		$66.9M Buy
900,879
+179,247
+25% +$12.7M 6% 2
2014
Q4 		$40.4M Sell
721,632
-62,827
-8% -$3.3M 4.4% 6
2014
Q3 		$35.6M Buy
784,459
+60,643
+8% +$2.53M 4.11% 4
2014
Q2 		$30M Buy
723,816
+210,618
+41% +$10.8M 3.64% 7
2014
Q1 		$35.5M Sell
513,198
-59,072
-10% -$4.34M 4.24% 5
2013
Q4 		$34.5M Buy
572,270
+100,925
+21% +$5.49M 4.26% 2
2013
Q3 		$28.6M Sell
471,345
-4,032
-0.8% -$286K 4.31% 6
2013
Q2 		$31.8M Buy
+475,377
New +$21.4M 5.61% 3

Other funds holding CLVS

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Redmile Group's CLVS Position: Q2 2020 in Review

Redmile Group sold out of Clovis Oncology, Inc. (CLVS) in Q2 2020, closing a stake of 99,485 shares — an estimated $633K sold.

Redmile Group first reported a position in CLVS in Q2 2013 and held it in 26 quarters. The position peaked at $113M in Q1 2019. 158 funds tracked by Wall St. Rank hold CLVS as of Q2 2020.

  • Redmile Group reported no remaining Clovis Oncology, Inc. position as of Q2 2020 after selling out during the quarter.
  • Redmile Group sold 99,485 Clovis Oncology, Inc. shares in Q2 2020, an estimated $633K.
  • Redmile Group first reported a position in Clovis Oncology, Inc. in Q2 2013 and held it in 26 quarters.
  • Redmile Group's Clovis Oncology, Inc. position peaked at $113M in Q1 2019.
  • 158 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q2 2020.

Based on Redmile Group's 13F filing for Q2 2020, filed 14 Aug 2020.